The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Medical Treatment of Advanced Testicular Cancer
Abstract
CONTEXT: The medical treatment of advanced testicular germ cell tumors has changed over the past 30 years, with long-term survival now achieved in the majority of patients. Clinicians need to be familiar with the available treatment regimens for testicular cancer and their associated toxic effects. OBJECTIVE: To review the treatments used for advanced testicular germ cell tumors and their associated short-term and long-term complications. EVIDENCE ACQUISITION: A search was performed of all English-language literature (1966 to October 2007) within the MEDLINE database using the terms neoplasms, germ cell, or embryonal or testicular neoplasms restricted to humans, drug therapy, complications, and mortality. The Cochrane Register of Controlled Trials Databases (through October 2007) was also searched using the terms testicular cancer or germ cell tumors. Bibliographies were reviewed to extract other relevant articles. One hundred eighty-six articles were selected based on pertinence to advanced testicular cancer treatment, associated complications, and late relapses with an emphasis on randomized controlled trials. DATA SYNTHESIS: The treatment of advanced testicular germ cell tumors with cisplatin combination chemotherapy is based on risk stratification (good, intermediate, or poor prognosis) according to pretreatment clinical features of prognostic value. Clinical trials have demonstrated that approximately 90% of patients classified as having a good prognosis achieve a durable complete remission to either 4 cycles of etoposide and cisplatin or 3 cycles of cisplatin, etoposide, and bleomycin. Complete responses are achieved less frequently for patients with intermediate- and poor-risk germ cell tumors, in whom 4 cycles of bleomycin, etoposide, and cisplatin remains the standard of care. Second- and third-line programs, including high-dose chemotherapy, also have curative potential. Chronic toxicities associated with therapy include cardiovascular disease, infertility, and secondary malignancies. Late relapses may also occur. CONCLUSIONS: Clinical trials have led to evidence-based treatment recommendations for advanced testicular cancer based on risk stratification. Clinicians should be familiar with the potential complications of these therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M., & Sitzer, M. (2007) · Circulation · doi:10.1161/circulationaha.106.628875 · Cited by 2,977
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440
Malik, S., Wong, N. D., Franklin, S. S., Kamath, T. V., L’Italien, G. J., Pio, J. R., & Williams, G. R. (2004) · Circulation · doi:10.1161/01.cir.0000140677.20606.0e · Cited by 1,848
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
Mead, G. M., Stenning, S. P., Cook, P. A., Fosså, S. D., Horwich, A., Kaye, S. B., Oliver, R. T. D., deMulder, P., deWit, R., Stoter, G., et al. (1997) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1,033
Second Cancers Among 40 576 Testicular Cancer Patients: Focus on Long-term Survivors
Travis, L. B., Fosså, S. D., Schonfeld, S. J., McMaster, M. L., Lynch, C. F., Storm, H., Hall, P., Holowaty, E., Andersen, A., Pukkala, E., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji278 · Cited by 823
Rutter, M. K., Meigs, J. B., Sullivan, L. M., D’Agostino, R. B., & Wilson, P. W. F. (2004) · Circulation · doi:10.1161/01.cir.0000136581.59584.0e · Cited by 664
Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer
Huddart, R. A., Norman, A., Shahidi, M., Horwich, A., Coward, D., Nicholls, J., & Dearnaley, D. P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.173 · Cited by 547
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer
Meinardi, M. T., Gietema, J. A., van der Graaf, W. T. A., van Veldhuisen, D. J., Runne, M. A., Sluiter, W. J., de Vries, E. G. E., Willemse, P. B. H., Mulder, N. H., van den Berg, M. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1725 · Cited by 489
Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer
Travis, L. B., Curtis, R. E., Fraumeni, J. F., Boice, J. D., Storm, H., Andersson, M., Hall, P., Bergfeldt, K., Holowaty, E., Clarke, E. A., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.19.1429 · Cited by 488
van den Belt-Dusebout, A. W., de Wit, R., Gietema, J. A., Horenblas, S., Louwman, M. W. J., Ribot, J. G., Hoekstra, H. J., Ouwens, G. M., Aleman, B. M. P., & van Leeuwen, F. E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5296 · Cited by 453
Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas
Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., Stuart, N., Rea, D., Bower, M., Fernando, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050078 · Cited by 422
Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Activating c-kit Gene Mutations in Human Germ Cell Tumors
Tian, Q., Frierson, H. F., Krystal, G. W., & Moskaluk, C. A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65419-3 · Cited by 408
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
Loehrer, P. J., Gonin, R., Nichols, C. R., Weathers, T., & Einhorn, L. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2500 · Cited by 397
Syndrome X and Mortality: A Population-based Study
Trevisan, M., Liu, J., Bahsas, F. B., Menotti, A., & for the Risk Factor and Life Expectancy Research Group (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009572 · Cited by 388
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours
O’Sullivan, J. M., Huddart, R. A., Norman, A. R., Nicholls, J., Dearnaley, D. P., & Horwich, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg020 · Cited by 378
Einhorn, L. H., Williams, S. D., Loehrer, P. J., Birch, R., Drasga, R., Omura, G., & Greco, F. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.3.387 · Cited by 367
Bajorin, D. F., Sarosdy, M. F., Pfister, D. G., Mazumdar, M., Motzer, R. J., Scher, H. I., Geller, N. L., Fair, W. R., Herr, H., & Sogani, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.598 · Cited by 354
Nichols, C. R., Tricot, G., Williams, S. D., van Besien, K., Loehrer, P. J., Roth, B. J., Akard, L., Hoffman, R., Goulet, R., & Wolff, S. N. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.7.932 · Cited by 353
Motzer, R. J., Nichols, C. J., Margolin, K. A., Bacik, J., Richardson, P. G., Vogelzang, N. J., Bajorin, D. F., Lara, P. N., Einhorn, L., Mazumdar, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4528 · Cited by 353
Nichols, C. R., Catalano, P. J., Crawford, E. D., Vogelzang, N. J., Einhorn, L. H., & Loehrer, P. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1287 · Cited by 348
Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular Cancer
van den Belt-Dusebout, A. W., Nuver, J., de Wit, R., Gietema, J. A., ten Bokkel Huinink, W. W., Rodrigus, P. T. R., Schimmel, E. C., Aleman, B. M. P., & van Leeuwen, F. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7193 · Cited by 345
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer
Bokemeyer, C., Berger, C., Hartmann, J., Kollmannsberger, C., Schmoll, H., Kuczyk, M., & Kanz, L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.226 · Cited by 339
Hematologic Neoplasia Associated with Primary Mediastinal Germ-Cell Tumors
Nichols, C. R., Roth, B. J., Heerema, N. A., Griep, J. A., & Tricot, G. J. K. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005173222004 · Cited by 335
Horwich, A., Sleijfer, D. T., Fosså, S. D., Kaye, S. B., Oliver, R. T., Cullen, M. H., Mead, G. M., de Wit, R., de Mulder, P. H., Dearnaley, D. P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.1844 · Cited by 333
Late relapse of testicular cancer.
Baniel, J., Foster, R. S., Gonin, R., Messemer, J. E., Donohue, J. P., & Einhorn, L. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1170 · Cited by 331
Beyer, J., Kramar, A., Mandanas, R., Linkesch, W., Greinix, A., Droz, J. P., Pico, J. L., Diehl, A., Bokemeyer, C., Schmoll, H. J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2638 · Cited by 323
Raynaud's Phenomenon: A Common Toxicity After Combination Chemotherapy for Testicular Cancer
VOGELZANG, N. J., BOSL, G. J., JOHNSON, K., & KENNEDY, B. J. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-95-3-288 · Cited by 296
Fertility, gonadal and sexual function in survivors of testicular cancer
Huddart, R. A., Norman, A., Moynihan, C., Horwich, A., Parker, C., Nicholls, E., & Dearnaley, D. P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602677 · Cited by 295
Korkola, J. E., Houldsworth, J., Chadalavada, R. S. V., Olshen, A. B., Dobrzynski, D., Reuter, V. E., Bosl, G. J., & Chaganti, R. S. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2445 · Cited by 292
Nichols, C. R., Williams, S. D., Loehrer, P. J., Greco, F. A., Crawford, E. D., Weetlaufer, J., Miller, M. E., Bartolucci, A., Schacter, L., & Einhorn, L. H. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.7.1163 · Cited by 288
Pico, J. L., Rosti, G., Kramar, A., Wandt, H., Koza, V., Salvioni, R., Théodore, C., LELLI, G., Siegert, W., Horwich, A., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi228 · Cited by 287
Mortality After Cure of Testicular Seminoma
Zagars, G. K., Ballo, M. T., Lee, A. K., & Strom, S. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.205 · Cited by 286
RAMAN, J. D., NOBERT, C. F., & GOLDSTEIN, M. (2005) · Journal of Urology · doi:10.1097/01.ju.0000177491.98461.aa · Cited by 285
Loehrer, P. J., Lauer, R., Roth, B. J., Williams, S. D., Kalasinski, L. A., & Einhorn, L. H. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-7-540 · Cited by 276
Paternity Following Treatment for Testicular Cancer
Brydøy, M., Fosså, S. D., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., & Dahl, O. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji339 · Cited by 272
Beyer, J., Schwella, N., Zingsem, J., Strohscheer, I., Schwaner, I., Oettle, H., Serke, S., Huhn, D., & Stieger, W. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1328 · Cited by 269
Evaluation of long-term toxicity after chemotherapy for testicular cancer.
Bokemeyer, C., Berger, C. C., Kuczyk, M. A., & Schmoll, H. J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2923 · Cited by 268
Treatment-Associated Leukemia Following Testicular Cancer
Travis, L. B. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.14.1165 · Cited by 254
Steyerberg, E. W., Keizer, H. J., Fosså, S. D., Sleijfer, D. T., Toner, G. C., Schraffordt Koops, H., Mulders, P. F., Messemer, J. E., Ney, K., & Donohue, J. P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1177 · Cited by 254
Risk of Contralateral Testicular Cancer: A Population-based Study of 29 515 U.S. Men
Fosså, S. D., Chen, J., Schonfeld, S. J., McGlynn, K. A., McMaster, M. L., Gail, M. H., & Travis, L. B. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji185 · Cited by 251
Second cancer risk following testicular cancer: a follow-up study of 1,909 patients.
van Leeuwen, F. E., Stiggelbout, A. M., van den Belt-Dusebout, A. W., Noyon, R., Eliel, M. R., van Kerkhoff, E. H., Delemarre, J. F., & Somers, R. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.415 · Cited by 250
Loehrer, P. J., Johnson, D., Elson, P., Einhorn, L. H., & Trump, D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.470 · Cited by 245
Strumberg, D., Brügge, S., Korn, M. W., Koeppen, S., Ranft, J., Scheiber, G., Reiners, C., Möckel, C., Seeber, S., & Scheulen, M. E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf058 · Cited by 232
Semen Quality and Reproductive Hormones Before Orchiectomy in Men With Testicular Cancer
Petersen, P. M., Skakkebæk, N. E., Vistisen, K., Rørth, M., & Giwercman, A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.941 · Cited by 230
DOLL, D. C., LIST, A. F., GRECO, F. A., HAINSWORTH, J. D., HANDE, K. R., & JOHNSON, D. H. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-48 · Cited by 225
Kollmannsberger, C., Beyer, J., Droz, J. P., Harstrick, A., Hartmann, J. T., Biron, P., Fléchon, A., Schöffski, P., Kuczyk, M., Schmoll, H. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3386 · Cited by 201
Noncancer Causes of Death in Survivors of Testicular Cancer
Fossa, S. D., Gilbert, E., Dores, G. M., Chen, J., McGlynn, K. A., Schonfeld, S., Storm, H., Hall, P., Holowaty, E., Andersen, A., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk111 · Cited by 197
Kaye, S. B., Mead, G. M., Fossa, S., Cullen, M., deWit, R., Bodrogi, I., van Groeningen, C., Sylvester, R., Collette, L., Stenning, S., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.692 · Cited by 186
Components of the metabolic syndrome in long-term survivors of testicular cancer
Haugnes, H. S., Aass, N., Fosså, S. D., Dahl, O., Klepp, O., Wist, E. A., Svartberg, J., Wilsgaard, T., & Bremnes, R. M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl372 · Cited by 183
Tissue plasminogen activator antigen and coronary heart disease Prospective study and meta-analysis
Lowe, G. (2004) · European Heart Journal · doi:10.1016/j.ehj.2003.11.004 · Cited by 179
Study of anxiety disorder and depression in long-term survivors of testicular cancer
Dahl, A. A., Haaland, C. F., Mykletun, A., Bremnes, R., Dahl, O., Klepp, O., Wist, E., & Fosså, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.061 · Cited by 176
Fertility after testicular cancer treatments
Huyghe, É., Matsuda, T., Daudin, M., et al. (2004) · Cancer · doi:10.1002/cncr.11950 · Cited by 167
Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis
George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., Gobbett, T. A., Heiber, D. J., Heerema, N. A., Ramsey, H. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.019 · Cited by 166
McIntyre, A., Summersgill, B., Grygalewicz, B., Gillis, A. J. M., Stoop, J., van Gurp, R. J. H. L. M., Dennis, N., Fisher, C., Huddart, R., Cooper, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0471 · Cited by 165
Nuver, J., Smit, A. J., Wolffenbuttel, B. H., Sluiter, W. J., Hoekstra, H. J., Sleijfer, D. T., & Gietema, J. A. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)01043-8 · Cited by 163
HENDRY, W. F., STEDRONSKA, J., JONES, C. R., BLACKMORE, C. A., BARREIT, A., & PECKHAM, M. J. (1983) · British Journal of Urology · doi:10.1111/j.1464-410x.1983.tb03423.x · Cited by 161
Blood Pressure and Body Mass Index in Long-Term Survivors of Testicular Cancer
Haugnes, H. S., Aass, N., Fosså, S. D., Dahl, O., Klepp, O., Wist, E., Wilsgaard, T., & Bremnes, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.882 · Cited by 160
Effect of chemo- or radiotherapy on sperm parameters of testicular cancer patients
Gandini, L., Sgrò, P., Lombardo, F., Paoli, D., Culasso, F., Toselli, L., Tsamatropoulos, P., & Lenzi, A. (2006) · Human Reproduction · doi:10.1093/humrep/del167 · Cited by 159
Kollmannsberger, C., Beyer, J., Liersch, R., Schoeffski, P., Metzner, B., Hartmann, J. T., Rick, O., Stengele, K., Hohloch, K., Spott, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.068 · Cited by 157
Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis
Oldenburg, J., Martin, J. M., & Fosså, S. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1836 · Cited by 151
Nuver, J., Smit, A. J., Sleijfer, D. T., van Gessel, A. I., van Roon, A. M., van der Meer, J., van den Berg, M. P., Burgerhof, J. G. M., Hoekstra, H. J., Sluiter, W. J., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.12.012 · Cited by 149
Fosså, S. D., Stenning, S. P., Gerl, A., Horwich, A., CLARK, P. I., Wilkinson, P. M., Jones, W. G., Williams, M. V., Oliver, R. T. D., Newlands, E. S., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690534 · Cited by 147
Severe Bleomycin-Induced Pneumonitis
White, D. A., & Stover, D. E. (1984) · CHEST Journal · doi:10.1378/chest.86.5.723 · Cited by 146
Schrader, M., M�ller, M., Sofikitis, N., Straub, B., Krause, H., & Miller, K. (2003) · Urology · doi:10.1016/s0090-4295(02)02264-1 · Cited by 146
Hinton, S., Catalano, P. J., Einhorn, L. H., Loehrer, P. J., Kuzel, T. M., Vaughn, D. J., & Wilding, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.158 · Cited by 146
Molecular cytogenetic analysis of i(12p)‐negative human male germ cell tumors
Rodrı́guez, E., Houldsworth, J., Reuter, V. E., Meltzer, P. S., Zhang, J., Trent, J. M., Bosl, G. J., & Chaganti, R. S. K. (1993) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870080405 · Cited by 145
Secondary neoplasms following treatment of malignant germ cell tumors.
Bokemeyer, C., & Schmoll, H. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1703 · Cited by 145
Late relapse of germ cell tumors after cisplatin-based chemotherapy
Gerl, A., Clemm, C., Schmeller, N. T., Hentrich, M., Lamerz, R., & Wilmanns, W. (1997) · Annals of Oncology · doi:10.1023/a:1008253323854 · Cited by 140
Long-term renal function after treatment for malignant germ-cell tumours
Fosså, S. D., Aass, N., Winderen, M., Børmer, O. P., & Olsen, D. R. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf048 · Cited by 130
The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors
Gerl, A., M�hlbayer, D., Hansmann, G., Wilfried, M. R. A. Z., & Hiddemann, W. (2001) · Cancer · doi:10.1002/1097-0142(20010401)91:7<1297::aid-cncr1132>3.0.co;2-z · Cited by 128
LATE RELAPSE OF TESTICULAR GERM CELL NEOPLASMS: A DESCRIPTIVE ANALYSIS OF 122 CASES
Dieckmann, K., Albers, P., Claßen, J., de Wit, M., Pichlmeier, U., Rick, O., Müllerleile, U., & Kuczyk, M. A. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000154013.96349.36 · Cited by 126
SALVAGE SURGERY OF CHEMOREFRACTORY GERM CELL TUMORS WITH ELEVATED TUMOR MARKERS
Albers, P., GANZ, A., HANNIG, E., Miersch, W. D. E., & MÜLLER, S. C. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67365-x · Cited by 119
Late recurrences of germ cell malignancies: a population-based experience over three decades
Oldenburg, J., Alfsen, G. C., Wæhre, H., & Fosså, S. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603014 · Cited by 112
Bajorin, D. F., Motzer, R. J., Rodriguez, E., Murphy, B. A., & Bosl, G. J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.60 · Cited by 112
Impaired Testicular Function in Patients With Carcinoma-In-Situ of the Testis
Petersen, P. M., Giwercman, A., Hansen, S. W., Berthelsen, J. G., Daugaard, G., Rørth, M. R., & Skakkebæk, N. E. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.173 · Cited by 107
Pectasides, D., Pectasides, M., Farmakis, D. T., Aravantinos, G., Nikolaou, M., Koumpou, M., Gaglia, A., Kostopoulou, V., Mylonakis, N., & Skarlos, D.-V. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh103 · Cited by 104
Alterations of the c‐kit gene in testicular germ cell tumors
Sakuma, Y., Sakurai, S., Oguni, S., Hironaka, M., & Salto, K. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01470.x · Cited by 103
Fosså, S. D., Langmark, F., Aass, N., Andersen, A., Lothe, R. A., & Børresen‐Dale, A. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.142 · Cited by 98
Controversies in the Management of Clinical Stage I Testis Cancer
de Wit, R., & Fizazi, K. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9434 · Cited by 94
Jacobsen, K. D., Ous, S., Wæhre, H., Trasti, H., Stenwig, A. E., Lien, H. H., Aass, N., & Fosså, S. D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690347 · Cited by 92
Increased mortality rates in young and middle-aged patients with malignant germ cell tumours
Fosså, S. D., Aass, N., Harvei, S., & Tretli, S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601558 · Cited by 84
Vaena, D. A., Abonour, R., & Einhorn, L. H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.067 · Cited by 83
Fertility in men with testicular germ cell tumors
Spermon, J. R., Kiemeney, L. A. L. M., MEULEMAN, E. J. H., Ramos, L., Wetzels, A. M. M., & Witjes, J. A. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00335-2 · Cited by 76
Mortality and incidence of second cancers following treatment for testicular cancer
Robinson, D., Møller, H., & Horwich, A. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603589 · Cited by 75
Sperm antibodies and infertility in patients with testicular cancer
Guazzieri, S., Lembo, A., Ferro, G., Artibani, W., Merlo, D. F., Zanchetta, R., & Pagano, F. C. (1985) · Urology · doi:10.1016/0090-4295(85)90046-9 · Cited by 73
Electroejaculation Following Retroperitoneal Lymphadenectomy
Ohl, D. A., Denil, J., Bennett, C. J., Randolph, J. F., Menge, A. C., & McCabe, M. (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)38507-5 · Cited by 72
Madani, A., Kemmer, K. A., Sweeney, C. J., Corless, C. L., Ulbright, T. M., Heinrich, M. C., & Einhorn, L. H. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg244 · Cited by 64
Rational Selection of Patients for Antibacterial Prophylaxis After Chemotherapy
Cullen, M. H., Billingham, L. J., Gaunt, C. H., & Steven, N. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.7395 · Cited by 62
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
Bedano, P. M., Brames, M. J., Williams, S. D., Juliar, B. E., & Einhorn, L. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8065 · Cited by 54
Nakai, Y., Nonomura, N., Oka, D., Shiba, M., Arai, Y., Nakayama, M., Inoue, H., Nishimura, K., Aozasa, K., Mizutani, Y., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.042 · Cited by 49
Health-Related Quality of Life in Survivors of Testicular Cancer 3 to 13 Years After Treatment
Rudberg, L., Nilsson, S. F., & Wikblad, K. F. (2000) · Journal of Psychosocial Oncology · doi:10.1300/j077v18n03_02 · Cited by 48
Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer
Nord, C., Fosså, S. D., & Egeland, T. A. M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600714 · Cited by 45
Primary central nervous system lymphoma as a secondary malignancy
DeAngelis, L. M. (1991) · Cancer · doi:10.1002/1097-0142(19910301)67:5<1305::aid-cncr2820670506>3.0.co;2-j · Cited by 44
Detection of antisperm‐antibodies in patients with primary testicular cancer
Foster, R. S., Rubin, L. R., McNulty, A. M., Bihrle, R., & Donohue, J. P. (1991) · International Journal of Andrology · doi:10.1111/j.1365-2605.1991.tb01080.x · Cited by 40
Schairer, C., Hisada, M., Chen, B. E., Brown, L. M., Howard, R. A., Fosså, S. D., Gail, M. H., & Travis, L. B. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm081 · Cited by 39
Höbarth, K., Klingler, H. C., Maier, U., & Kollaritsch, H. (2010) · Urologia Internationalis · doi:10.1159/000282598 · Cited by 31
Mano, M. S., Guimarães, J. L., Sutmöller, S. F. M. C., Reiriz, A. B., Sutmöller, C. S. S. C., & Leo, A. D. (2006) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802006000600009 · Cited by 16
Arterial occlusive events during chemotherapy for germ cell cancer
Vos, A. (2001) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(01)00173-5 · Cited by 15
Cited by
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Microbial drug discovery: 80 years of progress
Demain, A. L., & Sanchez, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.16 · Cited by 1,002
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
“As a matter of fact, CDDP is highly efficient only against testicular germ cell cancer, leading to a durable complete remission in 480% of the patients.(10,11) Conversely, the clinical responses elicited by CDDP-based chemo(radio) therapeutic regimens in patients affected by other solid tumors (e.”
BackgroundCheng, L., Albers, P., Berney, D. M., Feldman, D. R., Daugaard, G., Gilligan, T., & Looijenga, L. H. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0029-0 · Cited by 462
Self-citation
Metadata
- Authors
- Feldman, D. R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-02-13
- Volume
- 299
- Issue
- 6
- Pages
- 672
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2160492795
- Cited by
- 370
- References
- 107
- FWCI
- 24.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.